How Bioretec Makes Orthopedic Implants Disappear + Medtronic’s Cole on the Growing Power of ASCs

In this episode of DeviceTalks Weekly, Host Tom Salemi and managing editor Kayleen Brown recap their recent West Coast tour—including a stop at the Santa Clara Convention Center, home of DeviceTalks West on Oct. 15–16. Register at West.DeviceTalks.com. They also share highlights from the MedtechVISION conference, including Kayleen’s brush with greatness—the winner of the Ferolyn Powell Award. This week’s FOMO segment features Medtronic’s Julie Cole, who updates listeners on the latest challenges and opportunities in the ASC sector in a conversation with DeviceTalks producer Emira Wininger. In the keynote interview, Tom sits down with Bioretec’s new CEO, Sarah van Hellenberg Hubar-Fisher, to talk about her career in MedTech and her decision to lead the company’s mission to transform orthopedic healing with advanced materials and bioabsorbable implants. Thanks for listening to DeviceTalks Weekly! *** Enjoy the show? Follow DeviceTalks Weekly on all major podcast players + Follow us on YouTube.com/@DeviceTalks to ensure you never miss an episode. Want access to the complete DeviceTalks Podcast Network (DTPN)? Follow us today at https://devicetalks.castos.com/subscribe Chapters (00:03:30) - MedtechVISION and the Ferolyn Powell award(00:06:38) - the Ferolyn Powell award winner(00:09:00) - Exciting Updates and Keynotes at DeviceTalks West Conference(00:12:55) - Connected Health DeviceTalks Tuesdays series(00:15:18) - FOMO – Medtronic’s Julie Cole on the Future of ASCs and MedTech Innovation(00:25:40) - Keynote Interview - Sarah Hubar-Fisher, CEO of Bioretec(00:32:28) - Challenges and Triumphs in MedTech Regulatory and Market Adoption(00:35:37) - Hubar-Fisher’s Journey from Corporate to Venture Capital and BioRetech(00:41:40) - BioRetech's Innovative Magnesium Alloy Implants for Orthopedic Solutions(00:49:06) - Bioretech's Journey to Market Leadership in Bioabsorbable Implants

There are no comments yet.

Please log in to write the first comment.